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Background
Bisphosphonates are frequently used for
prevention and treatment of osteoporosis. They
are also helpful in treating Paget’s disease of
bone, hypercalcemia associated with malignancy,
and osteolytic lesions associated with metastatic
bone disease and multiple myeloma. These bone
resorption inhibitors increase bone density by
binding to the bone matrix and slow down
osteoclastic
activity,
thereby
facilitating
1-5
The
bisphosphonate
osteoblastic effectiveness.
group of drugs include: alendronate (Fosamax),
etidronate (Didronel), ibandronate (Boniva),
pamidronate (Aredia), risedronate (Actonel),
tiludronate (Skelid), and zoledronic acid (Zometa)
in the U.S. In Canada alendronate (Fosamax),
clodronate
(Bonefos,
Ostac),
etidronate
(Didronel), pamidronate (Aredia), risedronate
(Actonel), and zoledronic acid (Zometa) are
available.4
Only Bonefos (or Ostac), Didronel, Aredia,
and Zometa are currently available in intravenous
dosage forms.4
The most common side effect of the oral
bisphosphonates is gastrointestinal upset.3 Postmarketing adverse event reports for both oral and
intravenous bisphosphonates have caused product
information changes in their labeling. Ocular side
effects such as nonspecific conjunctivitis, scleritis,
and uveitis have been reported.2 Recent reports
from several countries have revealed severe bone,
joint, and muscle pain associated with
bisphosphonate use.5,6
In 2003 and 2004, there were several reports of
osteonecrosis of the jaw (ONJ) in cancer patients
receiving chronic intravenous bisphosphonates.7-9
The reports associated pamidronate (Aredia) and
zoledronic acid (Zometa) with ONJ. Both
products
are
produced
by
Novartis
Pharmaceuticals Corporation and used for treating
hypercalcemia of malignancy. As a result, the
products’ labeling was updated in the U.S. in

August 2004 and in Canada in December 2004 to
include precautions about ONJ.10-12

Osteonecrosis of the Jaw
Osteonecrosis, also called avascular necrosis
of the bone or osteochondritis dissecans, is the
death of bone resulting in the collapse of the
bones’ structural architecture. It leads to bone
pain, loss of bone function, and bone destruction.
It is the result of a number of conditions leading to
an impairment of the blood supply to the bone.13
Systemic corticosteroid therapy is a risk factor
for osteonecrosis.
Osteonecrosis is a well
documented
complication
of
anti-cancer
treatment. Jaw bone is particularly vulnerable to
osteonecrosis because of tooth and gum
susceptibility to infection. Special added risk
factors for ONJ are trauma, as from dental
procedures, and local anesthetics.14
Bisphosphonates may present a unique role in
the initiation of ONJ because of their novel
antiangiogenic effects. Wood et al identified that
zoledronic acid has marked antiangiogenic
properties which could enhance its efficacy in
treatment of malignant bone disease.15 At the
same time this property may increase the risk of
ONJ. In addition, because bisphosphonates are
not metabolized, they remain in bone tissue for
long periods of time.9
Oral bisphosphonates have not been reported
to have the same degree of association with ONJ
as the intravenous products. In a 2004 report from
the FDA Adverse Event Reports database a total
of 139 cases of osteonecrosis were identified from
the marketing approval date of Aredia, Zometa,
Fosamax, and Actonel until May 24, 2004.
Thirty-four percent were associated with Aredia
use, 24% per associated with Zometa, 42% per
associated with patients who received both Aredia
and Zometa, 8.6% were associated with Fosamax
use, and one case was associated with Actonel.
The majority of these patients were diagnosed
More. . .
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with osteonecrosis of the jaw. Some had a
diagnosis
of
mixed
osteonecrosis
and
osteomyelitis. Because of these findings, the
report stated that osteonecrosis may be a class
effect of the bisphosphonates.
The oral
bisphosphonates are not as potent as the
intravenous agents but they all have the same
Labeling for both
mechanism of action.16
Fosamax and Actonel is in the process of being
updated to include this class osteonecrosis risk.
Boniva labeling already has been updated.17

Commentary
The majority of cases with osteonecrotic jaw
lesions occurred after a dental extraction yet some
Because of this
occurred spontaneously.7-9
association with dental procedures, potential
preventative measures are suggested prior to
bisphosphonate initiation.
Preventative measures include:
• Avoiding any elective jaw procedure
• Baseline and routine dental exams including
panoramic jaw radiography
• Delaying bisphosphonate therapy, if risk
factors allow, to complete dental procedures
for teeth or dental structures with poor
prognosis
• Educating patients about the importance of
good oral hygiene, symptom reporting, and
regularly scheduled dental assessments18
Patients already receiving bisphosphonates
should:
• Maintain excellent oral hygiene and have
routine dental examinations
• Obtain routine dental cleanings where careful
attention is given to avoiding soft-tissue
injury
• Have aggressive nonsurgical management of
any dental infection
• Have root canal treatment if needed rather
than dental extraction when possible18
Patients with osteonecrosis or suspected
osteonecrosis should receive immediate attention
from an oral surgeon or dental oncologist.18
Suspected
problems
associated
with
bisphosphonates should be reported. To report
adverse events in the US, call the FDA
MEDWATCH program at 1-800-FDA-1088. The
MEDWATCH program is also available on-line at
www.fda.gov/medwatch. In Canada, call the
Canadian Adverse Drug Reaction Monitoring

Program at 1-866-234-2345.
The Canadian
adverse reaction reporting form can be found at:
http://www.hc-sc.gc.ca/hpfb-dgpsa/tpddpt/adverse_e.pdf. It should be completed and
faxed to 1-866-678-6789.
Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.
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